Stada-Arzneimittel AG reported earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported group revenue of EUR 477 million compared to EUR 443.4 million a year ago. Operating profit was EUR 71 million compared to EUR 46.2 million a year ago. Adjusted operating profit was EUR 73 million compared to EUR 67.9 million a year ago. EBITDA was EUR 96.9 million compared to EUR 77.2 million a year ago. Adjusted EBITDA was EUR 98.5 million compared to EUR 92.3 million a year ago. Consolidated profit was EUR 34.9 million or EUR 0.59 per share compared to EUR 19.4 million or EUR 0.33 per share a year ago. Adjusted profit was EUR 36.7 million or EUR 0.62 per share compared to EUR 39.3 million or EUR 0.67 per share a year ago. For 2013, the company continue to see sales growth in the area of 7% to 8%, a high single-digit figure there. The company said that tax rate will be below the last year. Last year, the company had 26%, The company affirms for 2014 the promised long period prognosis, after which with a group revenue level an EBITDA settled of about EUR 2.15 billion on of about EUR 430 million and a consolidated profit of about EUR 215 million are to be achieved at least.

In accordance with a contract signed today, Dr. Matthias Wiedenfels (40) is to become Chief Corporate Development & Central Services Officer which includes the areas Human Resources, Legal, IP/Patents, Compliance, Risk Management and Export Control at Stada-Arzneimittel AG. Dr. Wiedenfels will take up his Executive Board duties immediately. The Supervisory Board has appointed him as Executive Board member until December 31, 2016. In 2010, Dr. Wiedenfels also became Chief Compliance Officer. Since 2011, his responsibilities have also included Group Risk Management.

Stada-Arzneimittel AG, Q1 2013 Earnings Call, May 07, 2013